Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques
| Autor: | Sanaz Ameli, Erik V. Soloff, Avinash Kambadakone, Richard K. G. Do, Alexander R. Guimares, Marc Zins, Atif Zaheer, Guillermo Sangster, Eric P. Tamm, Ajit H. Goenka, Zhen J. Wang, Priya Bhosale, Hina Arif-Tiwari |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Radiography
Abdominal medicine.medical_specialty Urology medicine.medical_treatment Context (language use) Adenocarcinoma 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Neoadjuvant therapy Radiological and Ultrasound Technology medicine.diagnostic_test business.industry Gastroenterology Magnetic resonance imaging Combination chemotherapy Hepatology medicine.disease Primary tumor Clinical trial Functional imaging Pancreatic Neoplasms 030220 oncology & carcinogenesis Radiology business Carcinoma Pancreatic Ductal |
| Zdroj: | Abdominal radiology (New York). 45(12) |
| ISSN: | 2366-0058 |
| Popis: | Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States and is projected to be the second by 2030. Systemic combination chemotherapy is considered an essential first-line treatment for the majority of patients with PDA, in both the neoadjuvant and palliative settings. In addition, a number of novel therapies are being tested in clinical trials for patients with advanced PDA. In all cases, accurate and timely assessment of treatment response is critical to guide therapy, reduce drug toxicities and cost from a failing therapy, and aid adaptive clinical trials. Conventional morphological imaging has significant limitations, especially in the context of determining primary tumor response and resectability following neoadjuvant therapies. In this article, we provide an overview of current therapy options for PDA, highlight several morphological imaging findings that may be helpful to reduce over-staging following neoadjuvant therapy, and discuss a number of emerging imaging, and non-imaging, tools that have shown promise in providing a more precise quantification of disease burden and treatment response in PDA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink